Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 3402


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3402

License Grant
The University and Salk grant to Licensee, upon and subject to all terms and conditions of this Agreement:  a worldwide exclusive license under the Licensed Patents to manufacture, have manufactured, use, sell, rent and lease Licensed Products for the term provided hereof.
License Property
Whereas, Columbia is the assignee of U.S. Patent Application Serial No.614,350, entitled Autocatalytic Replication of Recombinant RNA and Salk and Columbia are coassignees of U.S. Patent Application Serial No. 852,692, entitled Replicative RNA Reporter System.

Licensed Products shall mean all assays, kits, compositions,  reagents used in assays, and Diagnostic Instruments for performing assays where Licensee realizes a profit on cumulative Net Sales of such Diagnostic Instruments, which relate  to RNA-based amplification/detection systems which employ exponential amplification of replicative RNA by QB Replicase or a  related enzyme, whether or not used in or on Diagnostic Instruments, and which are covered by a claim of a Licensed  Patent that has neither expired nor been declared invalid by a court of last resort (Issued Valid Claim), or which use Licensed Research Information. Licensed Products shall exclude  reusable physical structures such as, by way of example,  containment, filters, detection means, temperature control  elements, transport mechanisms, sonication means, mixing elements, film software, computing hardware, manuals, recording  devices, paper and packing.

Field of Use
The rights granted relate to RNA-based amplification/detection systems which employ exponential amplification of replicative RNA by QB Replicase or a related enzyme.

IPSCIO Record ID: 7119

License Grant
Licensor, government organization, grants (a) Under Initial Patents and Research Patents, a worldwide exclusive license, including the right to grant sublicenses, to make, have made, use and sell or otherwise dispose of Royalty-Bearing Products including the right to grant immunity from suit under Initial Patents and Research Patents to authorized third parties for the use and sale of such Royalty-Bearing Products hereunder.
License Property
(a)  U.S. Serial No. 08/004,993 entitled Diagnostic Assays And Kits For RNA Using RNA Binary Probes And A Protein That Is An    RNA-Directed RNA Ligase
(b) U.S. Serial No. 08/006,073 entitled Sensitive Nucleic Acid Sandwich Hybridization Assays And Kits by Tyagi et al., filed January 15, 1993 and otherwise designated as A38 by PHRI; and
(c) U.S. Serial No. 08/005,893 entitled Diagnostic Assays And Kits For RNA Using RNA Binary Probes And A Ribozyme Ligase by Lizardi et al., filed January 15, 1993 and otherwise designated as A39 by PHRI.
Field of Use
The Royalty-Bearing Product is used or expected to be used to perform a method or process within the scope of one or more claims of a pending patent application or an issued patent.

IPSCIO Record ID: 237263

License Grant
Licensor grants a non-exclusive, non-transferable license, without the right to sublicense, to Licensed Patents and Licensed Know-How to use the Instrument solely for the internal research and development activities.

Licensor grants a world-wide, non-exclusive, nontransferable license, without the right to sublicense, to make, use, sell, off er for sale and import Licensed Products for genotyping HAPâ„¢ Markers in all fields other than human and animal infectious diseases. Excluded from this grant is the right to make, sell, offer for sale or import the Licensors ProbeTecâ„¢ ET.

License Property
Licensed Know-How shall mean Licensors know-how related to Licensed Patents, the ProbeTecâ„¢ ET, and custom software for the ProbeTecâ„¢ ET. Licensed KnowHow shall also include, upon written request from Licensee, Licensors know-how necessary in the design and development of assays that utilize ProbeTecâ„¢ ET.

The patents include, but are not limited to, Nucleic Acid Target Generation,  Oligonucleotides for amplification and detection of hemochromatosis, and, Methods for detecting nucleic acid sequence variations.

Licensed Products shall mean any device, instrument, service, kit, composition of matter, material, product or component thereof that utilizes Licensed Know-How.

Instrument shall mean the Licensors ProbeTecâ„¢ ET installed in Licensees HAPâ„¢ Typing facility in New Haven, CT.

HAPâ„¢ Marker shall mean a polymorphism or any ordered combination of two or more polymorphisms present at a locus on a single chromosome that is contained in the Licensee HAPâ„¢ Database during the term of this Agreement or that is discovered from any gene where such discovery was made solely by employees of Licensee or others acting on behalf of Licensee, or, jointly by employees of Licensees or others acting on its behalf and employees of a HAPâ„¢ Partner or others acting on its behalf or for which a HAPâ„¢ Partner requests Licensee to develop genotyping assays or provide genotype data.

Licensor ProbeTecâ„¢ ET shall mean the clinical platform for infectious disease testing owned by Licensor using Strand Displacement Amplification Technology or SDA Technology and real time detection means.


1. US Patent No. 5,270,184, entitled 'Nucleic Acid Target Generation'

2. US Patent No. 5,422,252, entitled 'Simultaneous Amplification of Multiple Targets'

3. US Patent No. 5,455,166, entitled 'Strand Displacement Amplification'

4. US Patent No. 5,536,649, entitled 'Decontamination of Nucleic Acid Amplification Reactions'

5. US Patent No. 5,547,861, entitled 'Detection of nucleic acid amplification'

6. US Patent No. 5,648,211, entitled 'Strand Displacement Amplifcation Using Thermophilic Enzymes'

7. US Patent No. 5,624,825, entitled 'Simultaneous Amplification of Multiple Targets'

8. US Patent No. 5,691,145, entitled 'Detection of nucleic acids using G-quartets'

9. US Patent No. 5,712,124, entitled 'Strand Displacement Amplification'

10. US Patent No. 5,736,365 entitled 'Multiplex nucleic acid amplification'

11. US Patent No. 5,744,311 entitled 'Strand displacement amplification using thermophilic enzymes'

12. US Patent No. 5,840,487, entitled 'Internal controls for isothermal nucleic acid amplification reactions'

13. US Patent No. 5,863,736, entitled 'Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples'

14. US Patent No. 5,888,739, entitled 'Detection of nucleic acids using G-quartets and Itetraplexes'

15. US Patent No. 5,916,779, entitled 'Strand displacement amplification of RNA

16. US Patent No. 5,919,630, entitled 'Detection of nucleic acids by fluorescence quenching'

17. US Patent No. 5,928,869, entitled 'Detection of nucleic acids by fluorescence quenching'

18. US Patent No. 5,935,791, entitled 'Detection of nucleic acids by fluorescence quenching'

Field of Use
Licensee creates personalized medicines through the integration of pharmacogenomics into drug development and marketing.  The fields of human and animal infectious diseases are excluded from this license.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.